Shares of Tekmira Pharmacueticals (TKMR) fell about 11% on June 19 after the company reported that its TKM-Ebola-Guinea drug has been stopped in a mid-stage clinical trial after the company did a preliminary analysis. The preliminary results concluded that the trial reached a certain pre-defined statistical endpoint and even if it added more patients to the clinical trial it still wouldn't succeed. 

The Canadian company didn't release the full results but claims that it will soon. That doesn't matter because all investors need to know is that the TKM-Ebola-Guinea drug failed to show efficacy in patients with Ebola. Notably, this is one of the Ebola drugs being tested on patients in Sierra Leone. These patients in Sierra Leone in West Africa have the strain of Ebola that is responsible for the outbreak that started back in 2013 that has claimed the lives of more than 11,000 people. 

Tekmira's other Ebola drug is TKM-Ebola. That program is an early stage trial of another strain of the virus and only being tested in healthy patients. Upon successful model results expected later this year the company will have to take the next step and test it on infected patients.